### Appendix Table. Characteristics of cancer patients with suspected \( \beta \)-herpesvirus infection on the basis of DNAemia and clinical signs and symptoms*

| Study no. | Interval, mo† | Clinical status | Age, y | Chemo-therapeutics | Symptoms in addition to fever | Fever duration, d | Pertinent physical findings | General appearance | Pertinent laboratory values | Viral load (copies/mL) |
|-----------|--------------|----------------|-------|-------------------|-----------------------------|------------------|--------------------------|------------------|----------------------------|------------------------|
|           |              |                |       |                   |                             |                  |                          |                  |                            | WB     | PBMC | PL | LC | WB | PBMC | PL | LC |
| 23        | <1           | AML recurrence‡ | 5     | ARA-C, gemtuzumab, ozogamicin | Diarrhea                   | 6                | None                     | Well             | ANC 0, ALC 580, high-avidity antibody to HHV-6 | 1,560 | 495  | –  | –  | –  | –    | –  | –  |
| 19        | 1            | ALL in remission | 2.1   | Asparaginase, 6-MP, MTX, vincristine, decadron | URI                        | 1                | Hepatomegaly, red left tympanic membrane | Ill              |                            | NT     | NT   | 685 | NT | NT | –    | –  | –  |
| 25        | 2            | ALL in remission | 2.3   | Daunorubicin, MTX, vincristine, ARA-C | None                      | 1                | None                     | Well             | ANC 550, high-avidity antibody to HHV-6 | 58    | –    | –  | NT | –  | –    | –  | –  |
| 38        | 3            | Wilms tumor     | 1.9   | Actinomycin-D, vincristine | None                      | 1                | None                     | Well             | ANC 530, high-avidity antibody to HHV-6 | NT    | 97   | –  | NT | –  | –    | –  | NT |
| 29        | 5.4          | ALL in remission | 5.4   | 6-MP, MTX | URI                        | 1                | None                     | Well             | ALC 300, CMV IgG negative | –     | –    | –  | 26,300 | 25 | –    | –  | –  |

*AV, antiviral therapy; HHV-6B, human herpesvirus 6B; CMV, cytomegalovirus; WB, whole blood; PMBC, peripheral blood mononuclear cells; PL, plasma; LC, lymphocyte culture. AML, acute myeloid leukemia; ARA-C = cytarabine, ANC, absolute neutrophil count in cells/\( \mu \)L; ALC, absolute lymphocyte count in cells/\( \mu \)L; ALL, acute lymphoblastic leukemia; 6-MP, 6-mercaptopurine; MTX, methotrexate; URI, upper respiratory infection. AST, aspartate aminotransferase in U/L; ALT, alanine aminotransferase in U/L; NT, not tested (i.e., specimen not available or equipment failure); IgG, immunoglobulin G.

†Time between fever and onset of immune suppression.

‡We describe this patient as immune suppressed for <1 mo. This patient originally was treated for AML and had ended therapy 12 months before study enrollment.